AstraZeneca PLC (AZN) stock
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
AstraZeneca's revenue for the twelve months ending Jun 30, 2021 was $29.01B, up 16.2% year over year. For fiscal 2025 it was $58.74B, up 8.6% from the year before. Over ten years it grew 9.0% a year on average. The highest annual figure on record is $58.74B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.74B | +8.6% |
| FY2024 | Dec 31, 2024 | $54.07B | +18.0% |
| FY2023 | Dec 31, 2023 | $45.81B | +3.3% |
| FY2022 | Dec 31, 2022 | $44.35B | +18.5% |
| FY2021 | Dec 31, 2021 | $37.42B | +40.6% |
| FY2020 | Dec 31, 2020 | $26.62B | +9.2% |
| FY2019 | Dec 31, 2019 | $24.38B | +10.4% |
| FY2018 | Dec 31, 2018 | $22.09B | -1.7% |
| FY2017 | Dec 31, 2017 | $22.47B | -2.3% |
| FY2016 | Dec 31, 2016 | $23.00B | -6.9% |
| FY2015 | Dec 31, 2015 | $24.71B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $15.38B | +42.8% |
| Q2 FY2025 | Jun 30, 2025 | $14.46B | +75.9% |
| Q2 FY2024 | Jun 30, 2024 | $12.94B | +78.3% |
| Q2 FY2023 | Jun 30, 2023 | $11.42B | +62.8% |
| Q2 FY2022 | Jun 30, 2022 | $10.77B | +65.2% |
| Q2 FY2021 | Jun 30, 2021 | $8.22B | +31.0% |
| Q1 FY2021 | Mar 31, 2021 | $7.26B | +15.0% |
| Q4 FY2020 | Dec 31, 2020 | $7.01B | +12.2% |
| Q3 FY2020 | Sep 30, 2020 | $6.52B | +6.3% |
| Q2 FY2020 | Jun 30, 2020 | $6.28B | +7.8% |
| Q1 FY2020 | Mar 31, 2020 | $6.31B | +15.5% |
| Q4 FY2019 | Dec 31, 2019 | $6.25B | +8.4% |
| Q3 FY2019 | Sep 30, 2019 | $6.13B | +16.4% |
| Q2 FY2019 | Jun 30, 2019 | $5.82B | +13.0% |
| Q1 FY2019 | Mar 31, 2019 | $5.47B | +9.6% |
| Q4 FY2018 | Dec 31, 2018 | $5.77B | +5.1% |
| Q3 FY2018 | Sep 30, 2018 | $5.27B | +7.9% |
| Q2 FY2018 | Jun 30, 2018 | $5.16B | +4.4% |
| Q1 FY2018 | Mar 31, 2018 | $4.99B | +2.9% |
| Q4 FY2017 | Dec 31, 2017 | $5.49B | +4.3% |
| Q3 FY2017 | Sep 30, 2017 | $4.88B | -2.8% |
| Q2 FY2017 | Jun 30, 2017 | $4.94B | -9.7% |
| Q1 FY2017 | Mar 31, 2017 | $4.84B | -13.0% |
| Q4 FY2016 | Dec 31, 2016 | $5.26B | – |
| Q3 FY2016 | Sep 30, 2016 | $5.03B | – |
| Q2 FY2016 | Jun 30, 2016 | $5.47B | – |
| Q1 FY2016 | Mar 31, 2016 | $5.57B | – |
See a number that looks wrong?